Maternal T Cell Engraftment in SCID, Maternal Specimen
Also known as: SCID-MAT
Use
This test is used to monitor the engraftment of maternal T cells in patients with severe combined immunodeficiency (SCID) prior to allogenic stem cell transplantation. SCID patients often lack T cells and cannot effectively combat maternal T cells that may proliferate due to maternal-fetal transfusion, leading to complications such as graft-versus-host disease (GVHD). This test aids in assessing the presence and extent of maternal cell engraftment, which is crucial for managing SCID and preparing for potential stem cell transplantation.
Special Instructions
To complete the testing, samples should include: a buccal brush from the patient for pre-engraftment specimen analysis; a peripheral blood sample from the biological mother as a genetic baseline; and a peripheral blood sample from the patient for comparison. Additional charges apply if T-cell sorting is required but not completed before submission.
Limitations
Diagnostic errors can occur due to rare sequence variations. This test's performance characteristics were determined by ARUP Laboratories but have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The test is performed in a CLIA-certified laboratory for clinical use; however, it is not New York state approved.
Methodology
PCR-based (Fragment Analysis)
Biomarkers
Result Turnaround Time
5-9 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
2 mL
Minimum Volume
1 mL
Container
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A)
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 1 month |
| Frozen | unacceptable |